WASHINGTON, May 17, 2013 /PRNewswire-USNewswire/ -- Personalized medicine and targeted therapies hold great potential to improve patient care and health care efficiency. At the Ninth Annual State of Personalized Medicine Luncheon hosted by the Personalized Medicine Coalition (PC), Janet Woodcock, M.D., Director, Center for Drug Evaluation and Research at the Food and Drug Administration (FDA), will discuss how the FDA is dealing with the expanding field of personalized medicine, including the new program to encourage its development.
When: Tuesday, May 21, 2013
12:00 p.m. – 2:00 p.m. ET
Where: National Press Club, Ballroom
529 14th Street, NW
Washington, DC 20045
How To Register: Press may attend free of charge. For registration details, go to:
About the State of Personalized Medicine Luncheon: The annual PMC luncheon address event serves as a forum for PMC members and guest to engage with leaders in health care and to discuss key issues facing personalized medicine.
Previous keynote speakers at the State of Personalized Medicine Luncheon include Mr. Mark Levin, Partner and Co-Founder of Third Rock Ventures; Mr. John Castellani, President and CEO of PhRMA; Dr. Margaret Hamburg, Commissioner of the Food and Drug Administration; Dr. Denis Cortese, President and CEO of the Mayo Clinic; Dr. Harvey Fineberg, President of the Institute of Medicine; The Honorable Michael O. Leavitt, Secretary of Health and Human Services; Dr. Andrew von Eschenbach, Commissioner of the Food and Drug Administration; and Dr. Francis Collins, Director of the National Human Genome Research Institute.
About the Personalized Medicine Coalition: The Personalized Medicine Coalition (PMC), representing innovators, scientist, patients, providers and payer, promotes the understanding and adoption of personalized medicine concept, services and products to benefit the patient and the health system.
SOURCE Personalized Medicine Coalition